Biogen presents the first clinical data from an ongoing Phase 1 study of BIIB037 in mild to moderate Alzheimer’s

At the AD/PD 2013 meeting in Florence, Biogen presented the first clinical data from an ongoing Phase 1 trial, as well as new data on a direct comparison of mouse versions of BIIB037 to three other clinical antibodies - bapineuzumab (3D6), solanezumab (m266), and gantenerumab (mGt) - in vitro and in mice.